facebook twitter youtube

News archive

Recent news


From 29 to 31 May, the American Society of Clinical Oncology (ASCO) will hold its annual scientific meeting. This is the largest, and one of the most important, oncology meetings in the calendar year.

For the first time, ASCO20 will be held virtually adapting its programme and sessions to the COVID-19 situation. The programme will still feature over 250 oral abstract presentations and 2,500 poster presentations in 24 disease-based and speciality tracks. All presentations will be available on the ASCO20 website for a period of 180-days. Continue reading


Bristol Myers Squibb (BMS) and bluebird bio, Inc have announced that the companies received a Refusal to File letter from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory myeloma, which was submitted in March 2020. Continue reading